Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say

Dr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move anticipates the March 2026 patent expiry for the active ingredient in Novo Nordisk's Ozempic and Wegovy. The Indian drugmaker plans competitive pricing, aiming to capture a significant share of the growing diabetes and obesity market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rkOETu6
via IFTTT